Dr. Wang Shuai, MD, postdoctoral fellow at Harvard Medical School, master’s supervisor, and director of the Corneal Diseases and Corneal Transplantation Center at the Second Affiliated Eye Hospital of Dalian Medical University. Member of the Ophthalmology Branch of the Chinese Geriatrics Association, founder of the Dalian Medical Eye Dry Eye Clinic, which has been recognized as a demonstration base for dry eye diagnosis and treatment. As a key member of the Cepko Academician team at Harvard Medical School, she participated in FDA clinical translation projects in ophthalmology and was an Outstanding Fellow of the Massachusetts Eye Institute at Massachusetts General Hospital. She has led multiple research projects, including grants from the National Natural Science Foundation of China, the Liaoning Provincial Natural Science Foundation, central government-led local science and technology projects, and the Dalian Outstanding Young Science and Technology Fund. She was awarded the title of Dalian Outstanding Young Science and Technology Talent. She has published over 20 papers in top-tier journals, including high-impact articles as first/communicating author in Redox Biology (2018 IF: 11.799), Molecular Therapy (2020, IF: 11.454), Redox Biology (2022, IF: 10.607), and the classic ophthalmology journal IOVS (2020, IF: 4.799), with a total impact factor exceeding 100. Her research achievements were awarded the First Prize of the Liaoning Provincial Natural Science Academic Achievement Award. She holds 10 invention patents, 3 of which have been granted, and 2 have been commercialized. She received the Third Prize in the 9th China Clinical Innovation and Invention Competition. Her medical-engineering integration entrepreneurship project was selected for the Dalian Innovation and Venture High-Growth Enterprise Reserve.
Shuai Wang Tri Lab